List view / Grid view
8 June 2015 | By Victoria White
The Global Fertility Alliance is a new collaboration to advance excellence in fertility technologies within the assisted reproductive treatment laboratory...
3 June 2015 | By Victoria White
MSD has extended its existing collaborative research agreement with Agenus for the discovery and development of therapeutic antibodies...
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
8 April 2015 | By Victoria White
Arvinas to collaborate with MSD to use PROTAC technology to degrade target proteins, with the goal of creating novel therapeutics...
31 March 2015 | By Victoria White
Merck Serono and Intrexon Corporation have announced an exclusive collaboration and license agreement to develop and commercialise CAR-T cancer therapies...
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
23 June 2014 | By Merck
MSD is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
9 June 2014 | By Merck
MSD and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which MSD will acquire Idenix for $24.50 per share in cash...
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
2 May 2014 | By Merck
MSD and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...
11 February 2014 | By Merck
MSD and Samsung Bioepis Co., Ltd., announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293...
5 February 2014 | By Pfizer
Agreement to combine MSD’s investigational anti-PD-1 and key Pfizer oncology assets...
